Related Experiment Video
Updated: May 21, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Update Breast Cancer 2024 Part 3 - Patients with Advanced Stage Breast Cancer
Diana Lüftner1, Hans-Christian Kolberg2, Andreas D Hartkopf3
1Immanuel Hospital Märkische Schweiz, Buckow, Germany & Medical University of Brandenburg Theodor-Fontane, Rüdersdorf, Germany.
Abstract:
The use of CDK4/6 inhibitors, the new PI3K/AKT-kinase inhibitors, selective estrogen receptor-degraders (SERDs), antibody-drug conjugates, immune therapies and PARP inhibitors in recent years has resulted in a marked change in the therapy landscape for patients with advanced stage breast cancer. CDK4/6 inhibitors, trastuzumab deruxtecan, and sacituzumab govitecan have all been shown to provide significant overall survival benefits compared to conventional chemotherapy. Other substances are also showing promising results and hold out the hope that further analysis of the overall survival benefits will be available in the near future. The speed at which studies are now being carried out has markedly increased, and conferences and specialist journals are now constant sources of new information. This review summarizes the most recent publications and conference presentations on the treatment of patients with advanced stage breast cancer.
Insights
New therapies like CDK4/6 inhibitors and antibody-drug conjugates significantly improve survival for advanced breast cancer patients. This review covers recent advancements and promising treatments, offering hope for better outcomes.
Area of Science:
- Oncology
- Medical Therapeutics
Background:
- Advanced stage breast cancer treatment has evolved significantly.
- Conventional chemotherapy is being replaced by targeted therapies and immunotherapies.
Purpose of the Study:
- To review recent advancements in the treatment of advanced stage breast cancer.
- To summarize key findings from recent publications and conference presentations.
Main Methods:
- Literature review of recent publications.
- Analysis of conference presentations on breast cancer treatment.
Main Results:
- CDK4/6 inhibitors, trastuzumab deruxtecan, and sacituzumab govitecan demonstrate significant overall survival benefits.
- New PI3K/AKT-kinase inhibitors, SERDs, antibody-drug conjugates, immune therapies, and PARP inhibitors are emerging as promising treatments.
Conclusions:
- The therapeutic landscape for advanced breast cancer is rapidly changing with novel agents.
- Ongoing research and rapid study execution promise further improvements in patient survival.
Related Concept Videos
Cancer Survival Analysis
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

